Literature DB >> 15104297

Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract.

Donna E Hansel1, Robert E Wilentz, Charles J Yeo, Richard D Schulick, Elizabeth Montgomery, Anirban Maitra.   

Abstract

Neuropilin-1 (NRP-1) functions as an axonal guidance molecule in the developing nervous system, and recent work has identified NRP-1 up-regulation in several cancers, including neuroblastomas and breast carcinoma. We examined for the first time NRP-1 expression in a large variety of gastrointestinal carcinomas and precursor lesions to determine whether NRP-1 up-regulation correlated with invasive growth in this system. Protein expression and localization of NRP-1 were studied by immunolabeling and semiquantification in >300 dysplastic, invasive, and metastatic lesions of the gastrointestinal tract, and confirmation of NRP-1 protein expression was performed by Western blot analysis on pancreatic cancer cell lines. NRP-1 expression was limited within normal tissues of the gastrointestinal tract, with prominent labeling present only in endothelial cells, pancreatic islet cells, and the most apical colonic epithelium. Invasive cancer of the esophagus, gallbladder, ampulla of Vater, pancreas (endocrine and exocrine), and colon, however, all demonstrated striking NRP-1 expression. NRP-1 was also identified in precursor lesions of gastrointestinal adenocarcinomas, such as Barrett esophagus and colorectal adenomas. Within the spectrum of precursor lesions, a progressive increase in both intensity and area of expression was evident during histologic progression from low-grade to high-grade dysplasia. Notably, the most intense up-regulation of NRP-1 was apparent at or around the point of invasion, with focal expression of NRP-1 at levels equivalent to the invasive cancer (2- to 3-fold increase). Prominent labeling for NRP-1 was apparent in primary invasive cancers, liver metastases, and a subset of lymph node metastases, with a 2- to 3-fold increase of NRP-1 over dysplastic lesions. We conclude that increased expression of NRP-1 occurs in gastrointestinal adenocarcinomas and in a subset of high-grade precursor lesions. This up-regulation appears to parallel invasive behavior and may therefore be used as a potential marker for cancer aggressiveness in this system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104297     DOI: 10.1097/00000478-200403000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  45 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  Semaphorin 5A mediated cellular navigation: connecting nervous system and cancer.

Authors:  Abhilasha Purohit; Anguraj Sadanandam; Pavan Myneni; Rakesh K Singh
Journal:  Biochim Biophys Acta       Date:  2014-09-28

3.  Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.

Authors:  Silvia Coma; Akio Shimizu; Michael Klagsbrun
Journal:  Cell Adh Migr       Date:  2011-05-01       Impact factor: 3.405

4.  Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans.

Authors:  Yan Xin; Shuang Bai; Lisa A Damico-Beyer; Denise Jin; Wei-Ching Liang; Yan Wu; Frank-Peter Theil; Amita Joshi; Yanmei Lu; John Lowe; Mauricio Maia; Rainer K Brachmann; Hong Xiang
Journal:  Pharm Res       Date:  2012-06-16       Impact factor: 4.200

Review 5.  Neuropilins and liver.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

6.  Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients.

Authors:  Ricardo Saban; Marcia R Saban; Julie Maier; Ben Fowler; Mark Tengowski; Carole A Davis; Xue-Ru Wu; Daniel J Culkin; Paul Hauser; Joseph Backer; Robert E Hurst
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

7.  Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation.

Authors:  Danny C W Yu; Jennifer S Waby; Haridasan Chirakkal; Carolyn A Staton; Bernard M Corfe
Journal:  Mol Cancer       Date:  2010-10-15       Impact factor: 27.401

8.  Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells.

Authors:  Emely Castro-Rivera; Sophia Ran; Rolf A Brekken; John D Minna
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

9.  Chondroitin sulphate-modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas-mediated pathway.

Authors:  Paul Frankel; Caroline Pellet-Many; Pauliina Lehtolainen; Giovanna M D'Abaco; Michelle L Tickner; Lili Cheng; Ian C Zachary
Journal:  EMBO Rep       Date:  2008-08-15       Impact factor: 8.807

10.  Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity.

Authors:  H Jia; L Cheng; M Tickner; A Bagherzadeh; D Selwood; I Zachary
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.